UTHR
UNITED THERAPEUTICS Corp
-4.08 (-0.82%)494.40USD133K成交股數21.2B市值17.7本益比(近四季)6.7股價營收比-1.9%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 783M-2% | 782M-2% | 790M+6% | 800M+12% | 799M+18% | 794M+29% | 749M+23% | 715M+20% | 678M | 615M | 609M | 597M |
| 營業成本 | 99.5M | 133M | 103M | 101M | 87.6M | 92.5M | 83.1M | 77.8M | 72.9M | 71.0M | 70.1M | 64.1M |
| 毛利 | 684M-4% | 648M-8% | 687M+3% | 699M+10% | 711M+18% | 702M+29% | 666M+23% | 637M+20% | 605M | 544M | 539M | 532M |
| 毛利率 | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 88.9% | 89.1% | 89.2% | 88.4% | 88.5% | 89.3% |
| 研發費用 | 146M | 138M | 140M | 128M | 134M | 149M | 104M | 140M | 104M | 151M | 84.7M | 89.0M |
| 銷售管理費用 | 207M | 184M | 191M | 183M | 213M | 170M | 219M | 178M | 144M | 132M | 128M | 130M |
| 營業利益 | 331M-9% | 326M-15% | 357M+4% | 389M+21% | 365M+2% | 383M+47% | 343M+5% | 320M+2% | 356M | 260M | 327M | 313M |
| 營業利益率 | 42.2% | 41.7% | 45.1% | 48.6% | 45.6% | 48.2% | 45.8% | 44.7% | 52.6% | 42.3% | 53.7% | 52.5% |
| 稅後淨利 | 333M+8% | 275M-15% | 364M+18% | 339M+22% | 310M+1% | 322M+48% | 309M+16% | 278M+7% | 307M | 217M | 268M | 259M |
| 淨利率 | 42.5% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 41.3% | 38.9% | 45.2% | 35.3% | 43.9% | 43.5% |
| 稀釋 EPS | 7.27+13% | 5.82-12% | 7.66+20% | 7.16+22% | 6.41+4% | 6.63+53% | 6.39+19% | 5.85+12% | 6.17 | 4.33 | 5.38 | 5.24 |
| 稀釋股數 | 45.8M | 47.2M | 47.9M | 47.3M | 48.3M | 48.6M | 48.4M | 47.5M | 49.7M | 49.7M | 49.7M | 49.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.8B | 1.3B | 1.6B | 1.3B | 1.6B | 1.9B | 1.6B | 1.4B | 1.3B | 1.2B | 1.1B | 1.1B |
| 應收帳款 | 310M | 312M | 350M | 298M | 379M | 322M | 342M | 291M | 307M | 279M | 259M | 273M |
| 存貨 | 194M | 178M | 183M | 177M | 169M | 165M | 147M | 137M | 120M | 112M | 104M | 103M |
| 總資產 | 7.2B | 6.7B | 7.9B | 7.4B | 7.9B | 7.7B | 7.1B | 6.7B | 6.5B | 7.2B | 7.0B | 6.7B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 820M | 813M | 784M | 761M | 734M | 937M | 1.0B | 1.0B | 1.2B | 1.2B | 1.3B | 1.3B |
| 股東權益 | 6.4B | 5.9B | 7.1B | 6.6B | 7.2B | 6.8B | 6.1B | 5.7B | 5.3B | 6.0B | 5.7B | 5.4B |
| 負債比 | 11.4% | 12.1% | 9.9% | 10.4% | 9.3% | 12.1% | 14.4% | 15.3% | 17.8% | 16.5% | 18.7% | 19.0% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 463M+0% | – | – | – | 461M | – | – | 377M | – | – | – |
| 資本支出 | – | 101M | – | – | – | 74.9M | – | – | 38.2M | – | – | – |
| 自由現金流 | – | 363M-6% | – | – | – | 386M | – | – | 338M | – | – | – |
| 折舊攤銷 | – | 22.6M | – | – | – | 19.8M | – | – | 15.0M | – | – | – |
| 買回庫藏股 | – | 1.5B | – | – | – | 0.00 | – | – | 1.0B | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 46.4% | – | – | – | 48.6% | – | – | 49.9% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 3.2B
| 美國 | 3.0B | 95.4% | +10.9% |
|---|---|---|---|
| 美國以外 | 146M | 4.6% | +5.8% |
產品／服務2025 年度 · 778M
| Orenitram | 497M | 63.9% | +14.4% |
|---|---|---|---|
| Unituxin | 227M | 29.2% | -5.0% |
| Adcirca | 30.0M | 3.9% | +26.1% |
| Product And Service Other | 24.0M | 3.1% | +8.6% |
| Tyvaso 小計 | 1.9B | 241.5% | +15.9% |
| Tyvaso DPI 小計 | 1.3B | 166.2% | +25.0% |
| Nebulized Tyvaso 小計 | 586M | 75.3% | -0.2% |
| Remodulin 小計 | 527M | 67.7% | -2.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 3.2B | +10.6% | 1.3B | 41.9% | 27.86 | 1.0B |
| FY2024 | 2.9B | +23.6% | 1.2B | 41.5% | 24.64 | 1.1B |
| FY2023 | 2.3B | +20.2% | 985M | 42.3% | 19.81 | 748M |
| FY2022 | 1.9B | +14.9% | 727M | 37.6% | 15.00 | 664M |
| FY2021 | 1.7B | +13.6% | 476M | 28.2% | 10.06 | 477M |
| FY2020 | 1.5B | +2.4% | 515M | 34.7% | 11.54 | 696M |
| FY2019 | 1.4B | -11.0% | −105M | -7.2% | -2.39 | −290M |
| FY2018 | 1.6B | – | 589M | 36.2% | 13.39 | 594M |